Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nitrous Oxide · 2 trials · 2 indications
scales ranging from 0 - "no pain" to 10 - "worst pain ever" based on the PROMIS-29 v2.0 questionnaire.
| Arm | Type | Description |
|---|---|---|
| The nitrous oxide group | ACTIVE_COMPARATOR | Nitrous oxide group will receive 50% nitrous oxide mixed with 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit. |
| The Control Group | PLACEBO_COMPARATOR | Control group will receive 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit. |
| group 1 | ACTIVE_COMPARATOR | Colorectal surgery with 65% nitrous oxide administration |
| group 2 | ACTIVE_COMPARATOR | Colorectal surgery with nitrogen administration |
| Name | Type | Description |
|---|---|---|
| Nitrous Oxide | DRUG | A total of three inhalation treatments with 50% Nitrous Oxide plus 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session. |
| Oxygen | DRUG | A total of three inhalation treatments with 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session. |
| nitrogen | DRUG | Nitrogen administration during surgery |
Inclusion Criteria: 1. Patients must be diagnosed with CRPS based on the revised International Association for the Study of Pain criteria. 2. Duration of disease must be at least 6 months. 3. Written informed consent. Exclusion Criteria: 1. Patients who had no subjective benefit from ketamine inf...
Nitrous Oxide is being studied for use in Complex Regional Pain Syndrome and Colorectal Cancer. In clinical trials, it is evaluated as a treatment for these conditions, with studies examining its effect on cancer recurrence after colorectal surgery and its potential as a therapy for Complex Regional Pain Syndrome.
Nitrous Oxide is being developed by Community Health Systems, Inc., a company traded under the ticker CYH. The company is conducting clinical trials to evaluate the drug's efficacy in treating Complex Regional Pain Syndrome and Colorectal Cancer.
Nitrous Oxide is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing trials are designed to assess its safety and effectiveness in the studied indications.
Nitrous Oxide has been studied in two Phase 3 trials. One trial, NCT00781352, examined its effect on cancer recurrence after colorectal surgery in 408 patients with Colorectal Cancer. Another trial, NCT03879538, evaluated its use for Complex Regional Pain Syndrome in 44 patients. Both trials are completed.
Nitrous Oxide is a small molecule that acts as an anesthetic and analgesic agent. Its mechanism of action involves modulating neurotransmitter systems in the central nervous system, which can produce pain-relieving effects. This mechanism is relevant to its potential use in pain-related conditions.